Sophie Warembourg1, Majd Labaki2, Renaud de Tayrac2, Pierre Costa3, Brigitte Fatton2. 1. Gynecology Department, Urogynecology Unit, Nîmes Hospital, Nîmes, France. sophie.warembourg@chu-nimes.fr. 2. Gynecology Department, Urogynecology Unit, Nîmes Hospital, Nîmes, France. 3. Urology Department, Urogynecology Unit, Nîmes Hospital, Nîmes, France.
Abstract
INTRODUCTION AND HYPOTHESIS: The use of mesh in pelvic organ prolapse (POP) surgery has become a widespread treatment option, but carries a risk of specific complications. The objective was to report the rate and type of reoperation for mesh-related complications after pelvic organ prolapse surgery in an urogynecological referral center over a period of 8 years. METHODS: A retrospective study was carried out including all patients operated for a mesh complication after prolapse surgery between September 2006 and September 2014 in the urogynecology unit in Nîmes hospital. RESULTS: Sixty-nine mesh complications were recorded among the 67 patients included. Surgical treatment of mesh-related complications accounted for 7% of all pelvic surgeries performed in our center. Thirty-two patients (47.8%) were referred from other centers and 35 patients (52.2%) were initially operated in our unit. The global rate of reintervention for mesh-related complications after prolapse repair performed in our unit was 2.8%. Of 69 mesh complications, 48 patients (71.6%) had transvaginal mesh (TVM) and 19 patients (28.4%) sacrocolpopexy (SCP). The indication for surgery was a symptomatic or large vaginal erosion (47.8%), symptomatic mesh contraction (20.3%), and infection (11.6%). The most frequent primary symptom was pelvic/perineal pain or dyspareunia (33.3% of cases). The mean time between initial mesh surgery and the reoperation for a complication was 33.4 months (95% CI, 24.5 to 42.2). Eleven patients (15.9%) required several interventions. In total, 77.9% of patients experienced complete recovery of symptoms after surgical management. CONCLUSION: In a referral center the global rate of reinterventions for mesh-related complications after POP repair is 2.8%. The surgical treatment of mesh complications appears to be a safe and effective procedure with cure of the symptoms in most cases.
INTRODUCTION AND HYPOTHESIS: The use of mesh in pelvic organ prolapse (POP) surgery has become a widespread treatment option, but carries a risk of specific complications. The objective was to report the rate and type of reoperation for mesh-related complications after pelvic organ prolapse surgery in an urogynecological referral center over a period of 8 years. METHODS: A retrospective study was carried out including all patients operated for a mesh complication after prolapse surgery between September 2006 and September 2014 in the urogynecology unit in Nîmes hospital. RESULTS: Sixty-nine mesh complications were recorded among the 67 patients included. Surgical treatment of mesh-related complications accounted for 7% of all pelvic surgeries performed in our center. Thirty-two patients (47.8%) were referred from other centers and 35 patients (52.2%) were initially operated in our unit. The global rate of reintervention for mesh-related complications after prolapse repair performed in our unit was 2.8%. Of 69 mesh complications, 48 patients (71.6%) had transvaginal mesh (TVM) and 19 patients (28.4%) sacrocolpopexy (SCP). The indication for surgery was a symptomatic or large vaginal erosion (47.8%), symptomatic mesh contraction (20.3%), and infection (11.6%). The most frequent primary symptom was pelvic/perineal pain or dyspareunia (33.3% of cases). The mean time between initial mesh surgery and the reoperation for a complication was 33.4 months (95% CI, 24.5 to 42.2). Eleven patients (15.9%) required several interventions. In total, 77.9% of patients experienced complete recovery of symptoms after surgical management. CONCLUSION: In a referral center the global rate of reinterventions for mesh-related complications after POP repair is 2.8%. The surgical treatment of mesh complications appears to be a safe and effective procedure with cure of the symptoms in most cases.
Authors: Farzeen Firoozi; Michael S Ingber; Courtenay K Moore; Sandip P Vasavada; Raymond R Rackley; Howard B Goldman Journal: J Urol Date: 2012-03-15 Impact factor: 7.450
Authors: Mariëlla I Withagen; Mark E Vierhout; Jan C Hendriks; Kirsten B Kluivers; Alfredo L Milani Journal: Obstet Gynecol Date: 2011-09 Impact factor: 7.661
Authors: Cristina B Geltzeiler; Elisa H Birnbaum; Matthew L Silviera; Matthew G Mutch; Joel Vetter; Paul E Wise; Steven R Hunt; Sean C Glasgow Journal: Int J Colorectal Dis Date: 2018-08-03 Impact factor: 2.571